AbbVie ABBV Other Neuroscience — Net revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AbbVie in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbbVie's other neuroscience — net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbbVie's other neuroscience — net revenues?
- AbbVie (ABBV) reported other neuroscience — net revenues of $125M in Q1 2026.
- How has AbbVie's other neuroscience — net revenues changed year-over-year?
- AbbVie's other neuroscience — net revenues decreased by 19.4% year-over-year, from $155M to $125M.
- What is the long-term trend for AbbVie's other neuroscience — net revenues?
- Over 4 years (2021 to 2025), AbbVie's other neuroscience — net revenues has grown at a -18.4% compound annual growth rate (CAGR), from $685M to $303M.
- What does other neuroscience — net revenues mean?
- This metric represents the total net sales generated from the company's secondary portfolio of neuroscience therapeutic products, excluding primary flagship brands. It captures revenue streams from specialized neurological treatments that contribute to the company's diversified pharmaceutical footprint. Monitoring this segment helps investors assess the performance of niche therapeutic assets and the company's ability to maintain a broad portfolio in the central nervous system market.